BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 36175619)

  • 21. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis.
    Clifford SC; Prowse AH; Affara NA; Buys CH; Maher ER
    Genes Chromosomes Cancer; 1998 Jul; 22(3):200-9. PubMed ID: 9624531
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Determination of the consequences of VHL mutations on VHL transcripts in renal cell carcinoma.
    Taylor C; Craven RA; Harnden P; Selby PJ; Banks RE
    Int J Oncol; 2012 Oct; 41(4):1229-40. PubMed ID: 22825683
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Deubiquitylase OTUD6B stabilizes the mutated pVHL and suppresses cell migration in clear cell renal cell carcinoma.
    Guo K; Wei Y; Wang Z; Zhang X; Zhang X; Liu X; Wu W; Wu Z; Zhang L; Cui CP
    Cell Death Dis; 2022 Feb; 13(2):97. PubMed ID: 35110537
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical and functional properties of novel VHL mutation (X214L) consistent with Type 2A phenotype and low risk of renal cell carcinoma.
    Sorrell AD; Lee S; Stolle C; Ellenhorn J; Grix A; Kaelin WG; Weitzel JN
    Clin Genet; 2011 Jun; 79(6):539-45. PubMed ID: 20560986
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Three novel germ-line VHL mutations in Hungarian von Hippel-Lindau patients, including a nonsense mutation in a fifteen-year-old boy with renal cell carcinoma.
    Losonczy G; Fazakas F; Pfliegler G; Komáromi I; Balázs E; Pénzes K; Berta A
    BMC Med Genet; 2013 Jan; 14():3. PubMed ID: 23298237
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel and recurrent germline mutations in the VHL gene in 5 Arab patients with Von Hippel-Lindau disease.
    Faiyaz-Ul-Haque M; Jamil M; Aslam M; Abalkhail H; Al-Dayel F; Basit S; Nawaz Z; Zaidi SHE
    Cancer Genet; 2020 May; 243():1-6. PubMed ID: 32179488
    [TBL] [Abstract][Full Text] [Related]  

  • 27. VHL gene mutations and their effects on hypoxia inducible factor HIFα: identification of potential driver and passenger mutations.
    Rechsteiner MP; von Teichman A; Nowicka A; Sulser T; Schraml P; Moch H
    Cancer Res; 2011 Aug; 71(16):5500-11. PubMed ID: 21715564
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genotype and phenotype correlation in von Hippel-Lindau disease based on alteration of the HIF-α binding site in VHL protein.
    Liu SJ; Wang JY; Peng SH; Li T; Ning XH; Hong BA; Liu JY; Wu PJ; Zhou BW; Zhou JC; Qi NN; Peng X; Zhang JF; Ma KF; Cai L; Gong K
    Genet Med; 2018 Oct; 20(10):1266-1273. PubMed ID: 29595810
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comprehensive characterization and building of National Registry of von Hippel-Lindau disease in Brazil.
    Dallagnol TN; Da Cás E; Junior OR; Casali-da-Rocha JC
    Mol Genet Genomic Med; 2023 Apr; 11(4):e2136. PubMed ID: 36625343
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease.
    Clifford SC; Cockman ME; Smallwood AC; Mole DR; Woodward ER; Maxwell PH; Ratcliffe PJ; Maher ER
    Hum Mol Genet; 2001 May; 10(10):1029-38. PubMed ID: 11331613
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Von Hippel-Lindau disease and sporadic renal cell carcinoma.
    Zbar B
    Cancer Surv; 1995; 25():219-32. PubMed ID: 8718521
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Case report: a synonymous VHL mutation (c.414A > G, p.Pro138Pro) causes pathogenic familial hemangioblastoma through dysregulated splicing.
    Liu F; Calhoun B; Alam MS; Sun M; Wang X; Zhang C; Haldar K; Lu X
    BMC Med Genet; 2020 Feb; 21(1):42. PubMed ID: 32106822
    [TBL] [Abstract][Full Text] [Related]  

  • 33. von Hippel-Lindau mutants in renal cell carcinoma are regulated by increased expression of RSUME.
    Tedesco L; Elguero B; Pacin DG; Senin S; Pollak C; Garcia Marchiñena PA; Jurado AM; Isola M; Labanca MJ; Palazzo M; Yankilevich P; Fuertes M; Arzt E
    Cell Death Dis; 2019 Mar; 10(4):266. PubMed ID: 30890701
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma.
    Perier A; Fregni G; Wittnebel S; Gad S; Allard M; Gervois N; Escudier B; Azzarone B; Caignard A
    Oncogene; 2011 Jun; 30(23):2622-32. PubMed ID: 21258414
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Somatic mutations of the von Hippel-Lindau disease gene in renal carcinomas occurring in patients with long-term dialysis.
    Inoue H; Nonomura N; Kojima Y; Shiba M; Oka D; Arai Y; Nakayama M; Takayama H; Nishimura K; Mori H; Okuyama A
    Nephrol Dial Transplant; 2007 Jul; 22(7):2052-5. PubMed ID: 17438007
    [TBL] [Abstract][Full Text] [Related]  

  • 36. VHL mutations linked to type 2C von Hippel-Lindau disease cause extensive structural perturbations in pVHL.
    Knauth K; Cartwright E; Freund S; Bycroft M; Buchberger A
    J Biol Chem; 2009 Apr; 284(16):10514-22. PubMed ID: 19228690
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic and epigenetic alterations in the von hippel-lindau gene: the influence on renal cancer prognosis.
    Smits KM; Schouten LJ; van Dijk BA; Hulsbergen-van de Kaa CA; Wouters KA; Oosterwijk E; van Engeland M; van den Brandt PA
    Clin Cancer Res; 2008 Feb; 14(3):782-7. PubMed ID: 18245539
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Absence of VHL gene alteration and high VEGF expression are associated with tumour aggressiveness and poor survival of renal-cell carcinoma.
    Patard JJ; Rioux-Leclercq N; Masson D; Zerrouki S; Jouan F; Collet N; Dubourg C; Lobel B; Denis M; Fergelot P
    Br J Cancer; 2009 Oct; 101(8):1417-24. PubMed ID: 19755989
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The von Hippel-Lindau tumor suppressor protein promotes c-Cbl-independent poly-ubiquitylation and degradation of the activated EGFR.
    Zhou L; Yang H
    PLoS One; 2011; 6(9):e23936. PubMed ID: 21949687
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Specific Localization of Missense Mutations in the VHL Gene in Clear Cell Renal Cell Carcinoma.
    Mikhailenko DS; Zhinzhilo TA; Kolpakov AV; Kekeeva TV; Strel'nikov VV; Nemtsova MV; Kushlinskii NE
    Bull Exp Biol Med; 2017 Aug; 163(4):465-468. PubMed ID: 28853079
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.